Led by Questa Capital, the Series B Will Fund an Expansion of the EnsoData Growth Team, Driving Adoption of AI Solutions that Streamline the Diagnosis and Monitoring of the Estimated 1 Billion People Living with Sleep Apnea Worldwide
EnsoData, an innovator in AI healthtech solutions, today announced a $20 million Series B financing led by Questa Capital. This new capital will enable EnsoData to accelerate adoption of its AI-powered sleep medicine solutions, improving the sleep care pathway for, in the US alone, an estimated 54 million patients suffering from sleep apnea.
“Traditional approaches in sleep medicine have left nearly 80% of patients undiagnosed and, of the 20% that are positively diagnosed, only 1 in 2 will be successfully treated,” stated Dr. Justin Mortara, Ph.D., President and CEO at EnsoData. “We need to expand patient access with simpler and more economic testing while embracing new approaches for sleep apnea therapies to improve this reality. EnsoData’s AI solutions are uniquely positioned to do both, and this Series B fundraise will allow us to rapidly scale our commercial team to deliver the next wave of AI-driven healthcare solutions.”
The EnsoData team is already growing, with the addition of a new Chief Commercial Officer, Bobby Cockrill, MBA, announced last month. “The appointment of Bobby is our first step toward establishing a substantial U.S. commercial team. His deep experience in diagnostics and managing strategic sales and sales operations is already having an exciting impact,” said Mortara.
“EnsoData has built a uniquely comprehensive platform that integrates disruptive, FDA-cleared clinical technologies across a complete care pathway,” stated Brian Butler, Partner at Questa Capital. “The team’s design discipline emphasizes usability and interoperability, an approach that has established EnsoData as a leader in sleep while positioning the company for future growth in adjacent specialties. We are thrilled to partner with such an experienced team at the helm of an innovative technology company.”
In addition to Questa Capital, existing investors participated in the Series B, including Zetta Venture Partners, Venture Investors Health Fund, Supermoon Capital, and Inspire Medical Systems.
About EnsoData
EnsoData is a healthcare technology company that uses artificial intelligence (AI) and machine learning (ML) technology to connect sleep disorder diagnosis to therapy, simplifying and accelerating the sleep care pathway for both physicians and patients. To date, EnsoData has helped impact the sleep care pathway for more than 2.5 million patients.
About Questa Capital
Questa Capital is a venture growth equity firm focusing on investments in expansion-stage healthcare companies. Questa partners with exceptional teams building the next generation of breakout healthcare companies. We invest in change that elevates patient experiences, reduces costs, and improves patient health. Questa is led by industry veterans in healthcare investment and operations who have invested in and advised more than 60 growth-stage companies. More information is available at questacapital.com.
Originally announced June 25th, 2025
No comments:
Post a Comment